Triple-Drug attack aims to wipe out Hard-to-Treat leukemia
NCT ID NCT02846623
First seen Jun 26, 2026 · Last updated Aug 11, 2026 · Updated 3 times
Summary
This phase 2 trial tests a combination of three drugs—atezolizumab, obinutuzumab, and venetoclax—in 50 adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, or Richter syndrome that has returned or not responded to prior treatment. The goal is to see if the combo can reduce cancer cells to undetectable levels (MRD-negative). The study is active but no longer recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Atezolizumab, obinutuzumab, and venetoclax
- What this could lead to
- If successful, this combination could offer a new treatment option for people with hard-to-treat CLL or Richter syndrome, potentially achieving deep remission with no detectable cancer cells.
- What could go wrong
- This is a small, early-phase trial (50 people) without a comparison group. The drug combo may cause serious side effects, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can a targeted drug boost the fight against an aggressive blood cancer?
- Can a Three-Drug combo outsmart High-Risk CLL?
- Can a gentler dose of zanubrutinib keep CLL at bay in the very elderly?
- Can a Two-Drug combo wipe out hidden leukemia cells?